Recombinant Human Plasma Gelsolin (rhu-pGSN)
Inflammasome-Driven Decompression Sickness
Key Facts
About BioAegis Therapeutics
BioAegis Therapeutics is pioneering a non-immunosuppressive approach to treating inflammatory diseases through its platform based on the recombinant human protein plasma gelsolin (pGSN). The company is clinical-stage, with a pipeline targeting both acute and chronic conditions driven by inflammation, supported by a strong intellectual property portfolio licensed from Harvard and other institutions. Recent milestones include securing a second FDA Fast Track designation in August 2025 for treating inflammasome-driven decompensation sickness, highlighting regulatory interest in its novel mechanism.
View full company profileAbout BioAegis Therapeutics
BioAegis Therapeutics is pioneering a non-immunosuppressive approach to treating inflammatory diseases through its platform based on the recombinant human protein plasma gelsolin (pGSN). The company is clinical-stage, with a pipeline targeting both acute and chronic conditions driven by inflammation, supported by a strong intellectual property portfolio licensed from Harvard and other institutions. Recent milestones include securing a second FDA Fast Track designation in August 2025 for treating inflammasome-driven decompensation sickness, highlighting regulatory interest in its novel mechanism.
View full company profile